RVL Pharmaceuticals plc Announces Prepackaged Reorganization

Lender to Provide Incremental Liquidity to Support Long-Term Growth Senior Secured Lender to Exchange Outstanding Debt into Equity of the Reorganized Entities Business Operations at U.S. Subsidiaries to Continue as They Pursue Strategic Plan RVLP Ordinary Shares Expected to be Cancelled BRIDGEWATER, N.J., Oct. 12, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (“RVL” or “the Company”), a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride o

Related Keywords

Delaware , United States , Brian Markison , Lisam Wilson , Ducera Partners , Revitalid Pharmaceutical Corp , Al Goodbody , Ptosis Association , Site Communications Inc , Ernst Young , United States Bankruptcy Court , Ropes Gray , Senior Secured Lender To Exchange Outstanding Debt , Company Board Of Directors , Pharmaceuticals Inc , Provide Incremental Liquidity , Support Long Term , Secured Lender , Exchange Outstanding Debt , They Pursue Strategic , Shares Expected , Athyrium Capital Management , Revitalid Pharmaceutical , Chief Executive Officer , Reorganization Information , Site Communications , The Company , Vl , Reorganization , Oxymetazoline Hydrochloride , Orp , Lepharoptosis , Subsidiaries ,